Literature DB >> 16335349

Clinical equivalence of generic clozapine.

Daniel J Healy1, Stephan Taylor, Mona Goldman, Kris Barry, Frederic Blow, Karen K Milner.   

Abstract

OBJECTIVE: To determine if mental health service utilization increases when patients are converted to generic clozapine.
METHOD: About 125 patients taking clozapine in a community mental health clinic were switched from Novartis Clozaril to generic clozapine (Mylan Pharmaceuticals). Serum clozapine levels were obtained 2 weeks before, and 2 weeks after, the switch to generic clozapine. The number of outpatient visits, emergency room visits, and hospitalizations in the year prior to the switch were compared to those in the year following the switch, to determine service utilization.
RESULTS: Psychiatric emergency room visits decreased, but clozapine serum levels, inpatient hospital days, partial hospital admissions, and outpatient psychiatrist visits did not change after the switch to generic clozapine.
CONCLUSIONS: There were no significant increases in mental health service utilization after the conversion to Mylan generic clozapine. The switch to Mylan generic clozapine was cost effective, as the reduction in pharmacy costs was not offset by increased utilization costs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16335349     DOI: 10.1007/s10597-005-5981-y

Source DB:  PubMed          Journal:  Community Ment Health J        ISSN: 0010-3853


  9 in total

1.  Case reports of the reemergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation.

Authors:  R Mofsen; J Balter
Journal:  Clin Ther       Date:  2001-10       Impact factor: 3.393

2.  The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders.

Authors: 
Journal:  J Clin Psychiatry       Date:  2003       Impact factor: 4.384

3.  A program to convert patients from trade-name to generic clozapine.

Authors:  Steven C Stoner; Jessica W Lea; Beth Dubisar; Patricia A Marken; Leonard V Ramlatchman; James Reynolds
Journal:  Pharmacotherapy       Date:  2003-06       Impact factor: 4.705

Review 4.  Generic clozapine: a cost-saving alternative to brand name clozapine?

Authors:  Gordon Tse; Deborah Thompson; Ric M Procyshyn
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

5.  Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients.

Authors:  N R Cutler
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

6.  Clinical effects of a randomized switch of patients from clozaril to generic clozapine.

Authors:  J C Kluznik; N H Walbek; M G Farnsworth; K Melstrom
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

7.  Branded versus generic clozapine: bioavailability comparison and interchangeability issues.

Authors:  Y W Lam; L Ereshefsky; G B Toney; C Gonzales
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

8.  Converting patients from brand-name clozapine to generic clozapine.

Authors:  T A Sajbel; G W Carter; R B Wiley
Journal:  Ann Pharmacother       Date:  2001-03       Impact factor: 3.154

9.  Branded versus generic clozapine for treatment of schizophrenia.

Authors:  Eugene H Makela; William D Cutlip; James M Stevenson; Jason M Weimer; Ehab S Abdallah; Raja S Akhtar; Ahmed S Aboraya; Erdogan Gunel
Journal:  Ann Pharmacother       Date:  2003-03       Impact factor: 3.154

  9 in total
  4 in total

Review 1.  Switching from brand-name to generic psychotropic medications: a literature review.

Authors:  Julie Eve Desmarais; Linda Beauclair; Howard C Margolese
Journal:  CNS Neurosci Ther       Date:  2010-11-30       Impact factor: 5.243

Review 2.  Rational use of generic psychotropic drugs.

Authors:  Maren Carbon; Christoph U Correll
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

Review 3.  Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?

Authors:  Brian Godman; William Shrank; Bjorn Wettermark; Morten Andersen; Iain Bishop; Thomas Burkhardt; Kristina Garuolienè; Marija Kalaba; Ott Laius; Roberta Joppi; Catherine Sermet; Ulrich Schwabe; Inês Teixeira; F Cankat Tulunay; Kamila Wendykowska; Corinne Zara; Lars L Gustafsson
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-05

4.  Potential to enhance the prescribing of generic drugs in patients with mental health problems in austria; implications for the future.

Authors:  Brian Godman; Anna Bucsics; Thomas Burkhardt; Jutta Piessnegger; Manuela Schmitzer; Corrado Barbui; Emanuel Raschi; Marion Bennie; Lars L Gustafsson
Journal:  Front Pharmacol       Date:  2013-01-07       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.